Issue: March 25, 2019
February 07, 2019
1 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Eyenovia’s MicroStat shows positive phase 3 data
Issue: March 25, 2019
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN FRANCISCO — Michael Rowe, vice president of marketing for Eyenovia, discusses results of the MIST-1 trial of MicroStat, a fixed combination of phenylephrine 2.5% and tropicamide 1%, and demonstrates how Eyenovia’s OpteJet technology works at the Glaucoma 360: New Horizons Forum.